Mixed da­ta does­n't stop this biotech uni­corn from plot­ting a loom­ing PhI­II show­down

Sa­mumed has of­ten found it eas­i­er to come up with lots more in­vestor cash than con­sis­tent­ly pos­i­tive clin­i­cal da­ta. And that odd jux­ta­po­si­tion has nev­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER